Description

OL-TRAM 100 mg (Tramadol Hydrochloride)

OL-TRAM 100 mg is an oral, centrally acting analgesic formulation containing tramadol hydrochloride. It provides multimodal pain relief through two complementary mechanisms: low-affinity binding as an agonist at $\mu$-opioid receptor sites, alongside the simultaneous inhibition of norepinephrine and serotonin ($\text{5-HT}$) neuronal reuptake. This dual pharmacodynamic action alters ascending nociceptive transmission while augmenting descending inhibitory pathways within the central nervous system.

Product Overview

Primary Indications

OL-TRAM 100 mg is prescribed under strict medical supervision for:

• Moderate to Moderately Severe Acute Pain: Short-term management of acute pain following surgical procedures, severe trauma, or orthopedic interventions when non-opioid analgesics (e.g., standard NSAIDs or paracetamol) prove inadequate or unsuitable.

• Refractory Chronic Pain: Management of persistent, severe pain conditions (such as advanced musculoskeletal disorders, degenerative joint disease, or neuropathic pain) requiring structured, around-the-clock opioid analgesia.

Key Information & Precautions

• Dosage & Daily Maximum Limits: Must be administered strictly in accordance with licensed physician instructions. The total daily dose of immediate-release tramadol should generally not exceed 400 mg per day in adults with normal renal and hepatic function (often capped at 300 mg daily in geriatric patients) to minimize toxicity and seizure risks.

• CYP2D6 Polymorphism & Therapeutic Variability: Tramadol’s opioid analgesic efficacy is heavily reliant on its enzymatic conversion into the more potent $\text{M1}$ metabolite by CYP2D6. Patients categorized as “poor metabolizers” may achieve suboptimal pain relief, whereas “ultra-rapid metabolizers” are at heightened risk of rapid toxicity, excessive sedation, and respiratory depression even at standard therapeutic doses.

• Seizure Vulnerability: Tramadol lowers the convulsive seizure threshold. Seizure risk escalates substantially at doses above the recommended range or when co-administered with epileptogenic agents, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics, or bupropion.

• Serotonin Syndrome Risk: Concurrent administration with serotonergic medications (e.g., MAOIs, triptans, linezolid, St. John’s Wort) can precipitate life-threatening serotonin toxicity, marked by hyperreflexia, autonomic instability, hyperthermia, clonus, and mental status changes.

• Abuse, Dependence, and Misuse Liability: Although tramadol has a lower binding affinity for $\mu$-opioid receptors relative to classical full agonists like morphine, it carries a confirmed liability for physical dependence, tolerance, non-medical diversion, and addiction.

• Atypical Withdrawal Complications: Abrupt cessation following regular therapy can trigger typical opioid withdrawal features (lacrimation, chills, diarrhea, tremors) combined with atypical neuro-rebound phenomena (intense anxiety, hallucinations, paresthesias) due to monoamine reuptake inhibition. Discontinuation requires a planned, gradual step-down taper.

• Boxed Warning — Concomitant CNS Depressants: Simultaneous use with benzodiazepines, other sedative-hypnotics, or alcohol dramatically amplifies the risk of profound sedation, life-threatening respiratory depression, coma, and fatal overdose.

• Psychomotor & Cognitive Impairment: Causes somnolence, dizziness, and decreased reaction speeds. Patients must be cautioned against driving, operating heavy machinery, or performing hazardous tasks while taking this medication.